APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma
- PMID: 27016308
- PMCID: PMC5026552
- DOI: 10.1158/1078-0432.CCR-15-2910
APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma
Abstract
Purpose: APOBEC3 DNA cytosine deaminase family members normally defend against viruses and transposons. However, deregulated APOBEC3 activity causes mutations in cancer. Because of broad expression profiles and varying mixtures of normal and cancer cells in tumors, including immune cell infiltration, it is difficult to determine where different APOBEC3s are expressed. Here, we ask whether correlations exist between APOBEC3 expression and T-cell infiltration in high-grade serous ovarian cancer (HGSOC), and assess whether these correlations have prognostic value.
Experimental design: Transcripts for APOBEC3G, APOBEC3B, and the T-cell markers, CD3D, CD4, CD8A, GZMB, PRF1, and RNF128 were quantified by RT-qPCR for a cohort of 354 HGSOC patients. Expression values were correlated with each other and clinical parameters. Two additional cohorts were used to extend HGSOC clinical results. Immunoimaging was used to colocalize APOBEC3G and the T-cell marker CD3. TCGA data extended expression analyses to additional cancer types.
Results: A surprising positive correlation was found for expression of APOBEC3G and several T cell genes in HGSOC. Immunohistochemistry and immunofluorescent imaging showed protein colocalization in tumor-infiltrating T lymphocytes. High APOBEC3G expression correlated with improved outcomes in multiple HGSOC cohorts. TCGA data analyses revealed that expression of APOBEC3D and APOBEC3H also correlates with CD3D across multiple cancer types.
Conclusions: Our results identify APOBEC3G as a new candidate biomarker for tumor-infiltrating T lymphocytes and favorable prognoses for HGSOC. Our data also highlight the complexity of the tumor environment with respect to differential APOBEC family gene expression in both tumor and surrounding normal cell types. Clin Cancer Res; 22(18); 4746-55. ©2016 AACR.
©2016 American Association for Cancer Research.
Conflict of interest statement
R.S.H. is a co-founder of ApoGen Biotechnologies Inc. The other authors have no conflicts of interest to disclose.
Figures




Similar articles
-
Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.Aging (Albany NY). 2020 Jun 16;12(12):11398-11415. doi: 10.18632/aging.103199. Epub 2020 Jun 16. Aging (Albany NY). 2020. PMID: 32544083 Free PMC article.
-
SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma.J Gynecol Oncol. 2024 Nov;35(6):e79. doi: 10.3802/jgo.2024.35.e79. Epub 2024 Mar 29. J Gynecol Oncol. 2024. PMID: 38606823 Free PMC article.
-
Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.Cancer Med. 2021 Jun;10(12):3905-3918. doi: 10.1002/cam4.3942. Epub 2021 May 5. Cancer Med. 2021. PMID: 33955198 Free PMC article.
-
Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.Clin Cancer Res. 2016 Feb 1;22(3):714-24. doi: 10.1158/1078-0432.CCR-15-1617. Epub 2015 Sep 18. Clin Cancer Res. 2016. PMID: 26384738
-
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Nat Rev Cancer. 2015. PMID: 26493647 Free PMC article. Review.
Cited by
-
Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.Blood. 2022 Dec 22;140(25):2684-2696. doi: 10.1182/blood.2021015020. Blood. 2022. PMID: 35914226 Free PMC article.
-
RNA binding to APOBEC deaminases; Not simply a substrate for C to U editing.RNA Biol. 2017 Sep 2;14(9):1153-1165. doi: 10.1080/15476286.2016.1259783. Epub 2016 Nov 21. RNA Biol. 2017. PMID: 27869537 Free PMC article. Review.
-
Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer.Front Immunol. 2021 Jun 23;12:692360. doi: 10.3389/fimmu.2021.692360. eCollection 2021. Front Immunol. 2021. PMID: 34248988 Free PMC article. Review.
-
Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.Cell Commun Signal. 2017 Jan 19;15(1):5. doi: 10.1186/s12964-016-0155-9. Cell Commun Signal. 2017. PMID: 28100240 Free PMC article. Review.
-
APOBEC3-Related Editing and Non-Editing Determinants of HIV-1 and HTLV-1 Restriction.Int J Mol Sci. 2025 Feb 12;26(4):1561. doi: 10.3390/ijms26041561. Int J Mol Sci. 2025. PMID: 40004025 Free PMC article. Review.
References
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
-
- Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41–4. - PubMed
-
- Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27− memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012;18:3281–92. - PubMed
-
- Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials